Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 6, 2018Annals of Internal Medicine

Nonalcoholic Fatty Liver Disease

View Full Paper
Ask AI
Bookmark
Share

Authors

XWXiao‐Jing WangNew York UniversityHMHarmeet MalhiMayo Clinic

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wang et al. (2018) studied this question.

synapsesocial.com/papers/6a6535f146879c080bcb3175https://doi.org/10.7326/aitc201811060
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe2016 · 1,321 citations
  2. 2Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening2016 · 1,036 citations
  3. 3The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial2017 · 563 citations